fluorouracil has been researched along with Asthenia in 10 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC)." | 9.11 | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. ( Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs." | 5.27 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018) |
| "The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC)." | 5.11 | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. ( Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "There was a significant difference in adverse effect and toxicity such as naupathia,fever, swirl, asthenia observed between two groups (P < 0." | 2.73 | [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. ( Li, T; Li, ZW; Wen, HC, 2007) |
| "Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
| "Capecitabine in combination with docetaxel given every 3 weeks has shown a high degree of activity in a number of tumor types, but at the expense of significant toxicity." | 2.71 | Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. ( Belani, CP; Chatta, GS; Egorin, MJ; Fakih, M; Friedland, DM; Jacobs, SA; Jung, LL; Potter, DM; Ramalingam, S; Ramanathan, RK; Shin, DM; Strychor, S; Tutchko, S; Zamboni, WC, 2005) |
| " This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds." | 2.69 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. ( Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pastorino, A | 1 |
| Di Bartolomeo, M | 1 |
| Maiello, E | 1 |
| Iaffaioli, V | 1 |
| Ciuffreda, L | 1 |
| Fasola, G | 1 |
| Di Costanzo, F | 1 |
| Frassineti, GL | 1 |
| Marchetti, P | 1 |
| Antoniotti, C | 1 |
| Leone, F | 1 |
| Zaniboni, A | 1 |
| Aprile, G | 1 |
| Zilocchi, C | 1 |
| Sobrero, A | 1 |
| Bordonaro, R | 1 |
| Liu, Y | 1 |
| Wu, W | 1 |
| Hong, W | 1 |
| Sun, X | 1 |
| Wu, J | 1 |
| Huang, Q | 1 |
| Martin-Romano, P | 1 |
| Sola, JJ | 1 |
| Diaz-Gonzalez, JA | 1 |
| Chopitea, A | 1 |
| Iragorri, Y | 1 |
| MartÃnez-Regueira, F | 1 |
| Ponz-Sarvise, M | 1 |
| Arbea, L | 1 |
| Subtil, JC | 1 |
| Cano, D | 1 |
| Ceniceros, L | 1 |
| Legaspi, J | 1 |
| Hernandez, JL | 1 |
| RodrÃguez, J | 1 |
| Pasquini, G | 1 |
| Vasile, E | 1 |
| Caparello, C | 1 |
| Vivaldi, C | 1 |
| Musettini, G | 1 |
| Lencioni, M | 1 |
| Petrini, I | 1 |
| Fornaro, L | 1 |
| Falcone, A | 1 |
| Han, JY | 1 |
| Lee, DH | 1 |
| Kim, HY | 1 |
| Hong, EK | 1 |
| Yoon, SM | 1 |
| Chun, JH | 1 |
| Lee, HG | 1 |
| Lee, SY | 1 |
| Shin, EH | 1 |
| Lee, JS | 1 |
| Kakolyris, S | 1 |
| Souglakos, J | 1 |
| Kouroussis, C | 1 |
| Androulakis, N | 1 |
| Samonis, G | 1 |
| Vardakis, N | 1 |
| Amarantidis, K | 1 |
| Agelaki, S | 1 |
| Mavroudis, D | 1 |
| Xenidis, N | 1 |
| Georgoulias, V | 1 |
| Mackey, JR | 1 |
| Tonkin, KS | 1 |
| Koski, SL | 1 |
| Scarfe, AG | 1 |
| Smylie, MG | 1 |
| Joy, AA | 1 |
| Au, HJ | 1 |
| Bodnar, DM | 1 |
| Soulieres, D | 1 |
| Smith, SW | 1 |
| Ramanathan, RK | 1 |
| Ramalingam, S | 1 |
| Egorin, MJ | 1 |
| Belani, CP | 1 |
| Potter, DM | 1 |
| Fakih, M | 1 |
| Jung, LL | 1 |
| Strychor, S | 1 |
| Jacobs, SA | 1 |
| Friedland, DM | 1 |
| Shin, DM | 1 |
| Chatta, GS | 1 |
| Tutchko, S | 1 |
| Zamboni, WC | 1 |
| Li, T | 1 |
| Li, ZW | 1 |
| Wen, HC | 1 |
| Pronk, LC | 1 |
| Vasey, P | 1 |
| Sparreboom, A | 1 |
| Reigner, B | 1 |
| Planting, AS | 1 |
| Gordon, RJ | 1 |
| Osterwalder, B | 1 |
| Verweij, J | 1 |
| Twelves, C | 1 |
1 review available for fluorouracil and Asthenia
| Article | Year |
|---|---|
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
7 trials available for fluorouracil and Asthenia
| Article | Year |
|---|---|
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore | 2018 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non- | 2003 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2004 |
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Docetax | 2005 |
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therap | 2007 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
2 other studies available for fluorouracil and Asthenia
| Article | Year |
|---|---|
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |